Ruairi J Mackenzie
Senior Science Writer
Ruairi started with Technology Networks in January 2018 after completing an undergraduate degree in Neuroscience at the University of Edinburgh and a Master’s in Clinical Neuroscience from the University of Cambridge. As a senior science writer, Ruairi covers a range of scientific news and articles, with a focus on the complexities and curiosities of the brain. Ruairi also looks after search engine optimization efforts on Technology Networks and created the site’s podcast, Opinionated Science, in 2020.
Latest content from Ruairi J Mackenzie
Technology Networks spoke to the co-founder of Field Trip Health, a Toronto-based provider of ketamine therapy, on why 2021 was such a significant year for psychedelics.VIEW
This article from Technology Networks breaks down the qualities of the key five psychedelics and the current research projects illuminating their clinical potential.VIEW
“I’ve Never Seen Anything as Effective”: Exploring the Combination of Psychedelics and Psychotherapy
“Ketamine is helpful as a medicine, but there’s so much more to be gained by adding the psychotherapy component,” says Dr Reid Robison, Novamind’s chief medical officer.VIEW
These well-known compounds have moved past decades of stigma to become well-studied therapeutics either approved or in trial to treat mental health conditions such as major depression and post-traumatic stress disorder.
On this week’s Opinionated Science, the team takes a look at the growing potential of psychedelic medicine. In this episode, we take a deep dive into four leading psychedelic compounds: psilocybin, MDMA, ketamine, and DMT.
The new study examined structural changes in the brain that might explain psilocybin’s enduring antidepressant effects.VIEW
In this special podcast collaboration with Technology Networks, we hear how cannabis edibles affect our bodies and brains and how the growing demand for edibles will see the creation of cannabis drinks and restaurants. Please bring snacks.
A new technology developed by researchers at the University of California Davis promises to fast-track the development of compounds that could exploit psychedelics’ therapeutic action without hallucinogenic side effects.VIEW